Welcome to the 2025 spring edition of the newsletter from the SCLC Patient Gateway—your place for the latest research and information about small cell lung cancer (SCLC). It has been an exciting few months with advances and new developments in the treatment of SCLC. For many decades researchers struggled to make progress in treating small cell lung cancer. Treatment options were limited to surgery, radiation, and chemotherapy. Now, In the past five years we’ve seen two immunotherapies, atezolizumab and durvalumab, emerge as exciting additions to treating extensive-stage SCLC (ES-SCLC). In 2024, tarlatamab-dlle, a new type of immunotherapy, received accelerated approval from the US Food and Drug Administration (FDA) to treat ES-SCLC in patients who were previously treated with chemotherapy. Recently, the results of a larger phase 3 study (DeLLphi-304) supported the approval by demonstrating significant improvement in overall survival compared to the standard-of-care chemotherapy. Treatment options are improving for limited-stage SCLC (LS-SCLC) as well. Durvalumab was approved by the FDA for treating LS-SCLC in 2024. This approval was based on results from the ADRIATRIC trial, which showed improved overall survival for patients with LS-SCLC when treated with durvalumab. Basic science continues to be a key factor in making progress in treating SCLC. As researchers learn about the tumor microenvironment and other fundamentals of SCLC, their findings allow us to develop new and improved treatment options. Because of the strong basic science foundation developed over the past several decades, the drug development pipeline is full of promising drugs—including bispecifics, cell therapies, and antibody-drug conjugates (ADCs)—all designed to treat SCLC. We are looking forward to seeing how these emerging treatments compare to our current options, and we are hopeful about exciting new treatments for SCLC on the horizon. Research NewsOncology - CancerNetwork Oncology - CancerNetwork OncoDaily Journal of Clinical Investigation OncLive OncLive FierceBiotech OncLive Get ConnectedJoin Us for the SCLC Virtual Meetup Can’t make it? Don’t worry, there’s a full list of virtual meetups to fit your schedule. Have You Seen?Small Cell Smashers Fireside Chats 5 Takeaways From the 2025 SCLC Hot Topics Meeting Integrative Oncology and Lung Cancer: Adding Complementary Therapy Staying Safe From Smoke, Pollution, and Dangerous Air Quality … and there is always so much more to explore on the SCLC Patient Gateway. If you were forwarded this email and you’d like to subscribe to this newsletter, you can sign up here. If you are looking for more LUNGevity Foundation news, check out LUNGevity’s monthly newsletter. If you need further assistance along your lung cancer journey, please email us at support@lungevity.org. Our team is always here to assist you. |